Directly supplementing with oral reduced glutathione (L-GSH), however, presents a fundamental pharmacokinetic challenge: GSH has a plasma half-life of approximately 1.6 minutes, undergoes rapid hydrolysis in the gut by intestinal -glutamyl transpeptidase (-GT), and cannot cross cell membranes intact requiring full breakdown into constituent amino acids and intracellular resynthesis
Safety and Research Limitations Importantly, No adequate clinical evidence defines safe human exposure, maximum tolerated dose, reproductive toxicity, carcinogenicity, genotoxicity, cardiovascular risk, liver safety, kidney safety, endocrine effects, or drug interactions
This means injections are needed only once or twice a week rather than daily
3 Prevention of AD is key to helping patients with DS extend their lives without the distress that often accompanies AD